http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2526120-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4d2536d25c606cf230e24d4f94045e92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6e616d3909eb58b1c2deafca5b147110 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_010d971fae9015e5f82fe6f4d6a41a6b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b81a8f957691ddac8d015d1a8464b218 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c8b23a60cc674625e80cbbb85c726dd5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4e5ad0d16515b94c3572773b965708be |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-52 |
| filingDate | 2011-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57553442a92fa514e87268c4c7ddd327 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59caa331f274f19df78363e40ba8e556 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed83a20928256e5ddc039fe98908baa3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf23cc3aee3c25b534f9ef18b994474e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d10a7ad88db2200927de72a12a1b36b7 |
| publicationDate | 2014-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2526120-C2 |
| titleOfInvention | Method for prediction of clinical effectiveness in patients suffering from lung cancer |
| abstract | FIELD: medicine. n SUBSTANCE: invention refers to medicine, namely to oncology, and can be used for the prediction of integrated clinical effectiveness in the patients suffering from lung cancer in an early postoperative period. Substance of the invention consists in the fact that a patient's blood plasma α-1-proteinase inhibitor is measured for the first postoperative day and perioperative autochemoimmunotherapy. If observing an increase of the derived value by 28% and more as related to the common norm, the treatment is predicted to be effective, while a variation of less than 28%, no variations, or a decrease as compared to the norm show ineffective treatment. A specificity of the method for the instant prediction of integrated clinical effectiveness at the initial stages is 80.9%, and for the prediction of no effectiveness - 97%. n EFFECT: using the method provides high specificity, enabling instant objective evaluation of integrated clinical effectiveness at the initial stages, carrying out cito analysis, as well as prescribing well-timed adequate therapeutic measures or replacing the treatment. n 4 ex |
| priorityDate | 2011-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 54.